Cancer News and Research

Latest Cancer News and Research

University of Surrey lecturer on Co-sleeping

The event will be a series of overlapping presentations based on video clips of older people talking about their experience of poor sleep, and the impact this has on their lives. The presenters are all involved in the SomnIA (Sleep in Ageing) project based at the University of Surrey. As well as the video-based presentations and discussions, members of the audience will be invited to share some of their own experiences of poor sleep, and write down questions which they would like the panel of presenters to address during the last part of the event.

11 Sep 2009

Immigration and education policies to impact United states' leadership in science and discovery

Immigration and education policy experts gathered on Capitol Hill today to address the impact of policies related to U.S. medical innovation. The briefing, titled Education & Immigration: The Building Blocks of Innovation, was sponsored by the Council for American Medical Innovation as the first in a three-part series, Recovery Through Discovery, which examines medical innovation as a driver of U.S. economic recovery and enhanced global leadership in science.

11 Sep 2009

Abell Foundation plays major role in BioMarker's $1.7M private placement funding

BioMarker Strategies announced today that it has raised $1.7 million in a private placement funding round that occurred in conjunction with the Maryland Biotechnology Investment Incentive Tax Credit Program. BioMarker Strategies is developing the patent-pending, SnapPath™ testing system to enable oncologists to determine the most effective drug treatment for their cancer patients.

11 Sep 2009

Genspera to commence G-202 Phase I trial following FDA approval

GenSpera, Inc. announced today that the Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application to begin a Phase I study with its target activated pro-drug, G-202, for the treatment of cancer.

11 Sep 2009

USPTO allows Isis an additional patent for single-stranded RNAi technology

Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) and Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) announced today that the United States Patent and Trademark Office (USPTO) has allowed an Isis patent application that further expands the scope of the "Crooke" patent estate. The newly allowed patent broadly covers methods of cleaving a target RNA via a double-stranded ribonuclease mechanism, including the RNAi mechanism, with chemically modified, single-stranded RNA-containing drugs.

11 Sep 2009

RWJF selects Regions Hospital to take part in its effort to improve cardiac care delivered in hospitals

MN Community Measurement today announced that Regions Hospital has been selected by the Robert Wood Johnson Foundation (RWJF) to participate in a new effort to improve the quality -- and equality -- of cardiac care delivered in hospitals. The Aligning Forces for Quality: Equity Quality Improvement Collaborative (Equity QI Collaborative) will identify and test ways for hospitals to improve the quality and efficiency of their cardiac care, while also identifying and reducing any racial and ethnic disparities.

11 Sep 2009

Delcath Systems to continue Phase III clinical trial

Delcath Systems, Inc., a medical technology company testing its proprietary treatment method for primary and metastatic cancers to the liver, announced that the Data and Safety Monitoring Board ("DSMB") reviewed clinical data on 77 patients enrolled in its pivotal Phase III clinical trial and unanimously recommended that the trial continue to enroll patients with the goal of reaching the 92 patients required to complete the study.

11 Sep 2009

Roche scientists use their xCELLigence System to analyze nutlin-induced apoptosis

The p53 tumor suppressor, a transcription factor that activates or inhibits hundreds of genes, either directly or indirectly, triggers a variety of cellular effects and plays a central role in the cellular defense against cancer. One of the main approaches for pharmacological intervention is to activate wild-type p53 in cancer cells by blocking MDM2 from binding to p53.

11 Sep 2009

Abstracts on Merck Serono oncology treatments to be presented at ECCO and ESMO

Merck Serono, a division of Merck KGaA, Darmstadt, Germany, continues to drive the global effort to ensure patients receive personalized cancer therapies. A total of 17 abstracts concerning Merck Serono oncology treatments will be presented at the joint 15th Congress of the European Cancer Organisation (ECCO) and 34th Congress of the European Society for Medical Oncology (ESMO), to be held in Berlin from 20-24 September 2009.

11 Sep 2009

Hospital of Saint Raphael implements Think First’s Instant Informatics revenue cycle tool

Think First announced today that the Hospital of Saint Raphael’s Faculty Practice Plan (New Haven, CT) has implemented Think First’s Instant Informatics, a robust, best-practice revenue cycle tool that enables physician practices to measure, transform, and sustain organizational performance, drive up physician practice revenue, and achieve operational improvements.

11 Sep 2009

Solos obtains purchase order for surgical endoscopy instruments

Solos Endoscopy, Inc. (Pink Sheets: SNDY) is pleased to announce that the Company has received a purchase order for the MammoView(TM) line of surgical endoscopy instruments from the University of Missouri Health System, which boasts one of the most comprehensive health-care networks in Missouri.

11 Sep 2009

New stem cell technology could destroy breast cancer cells

GENova Biotherapeutics, Inc., ("GENova"), released important information about its innovative method for destroying breast cancer cells, using stem cell technology.

11 Sep 2009

HHS Secretary to issue new report on the employer-sponsored insurance market

HHS Secretary Kathleen Sebelius today will address the University of Chicago’s dialogue on health care reform and education and issue a new report on the employer-sponsored insurance market.

11 Sep 2009

ThromboGenics shortlisted for two awards at the Scrip Awards 2009

ThromboGenics NV, a biotechnology company focused on the discovery and development of innovative treatments for eye disease, vascular disease and cancer, announced today that it has been shortlisted for both the "Biotech Company of the Year" and "Licensing Deal of the Year" awards at the Scrip Awards 2009.

11 Sep 2009

Update on Prolindac clinical development plan provided by Access Pharmaceuticals

ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP), provided an update today on the Company's clinical development plan for ProLindac, a novel DACH platinum drug that has shown to be active in many solid tumor types in human clinical studies.

11 Sep 2009

Cellular mechanosensory system may yield new insights for cancer therapy

Every moment, millions of a body's cells flawlessly divvy up their genes and pinch perfectly in half to form two identical progeny for the replenishment of tissues and organs - even as they collide, get stuck, and squeeze through infinitesimally small spaces that distort their shapes.

11 Sep 2009

Amylin and Biocon collaborate to develop a peptide therapeutic for treating diabetes

Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) and Biocon, Limited (NSE: BIOCON) announced today that they have entered into an exclusive agreement to jointly develop, commercialize and manufacture a novel peptide therapeutic for the potential treatment of diabetes. Amylin and Biocon will collaborate to develop the therapeutic potential of the compound and share development costs. Research will center on Amylin's "phybrid" technology.

11 Sep 2009

New data reveals the efficacy of Instanyl in management of breakthrough cancer pain

New data presented today further demonstrate the efficacy of Instanyl in management of breakthrough cancer pain. The data which were presented at the 6th congress of the European Federation of Chapters of the International Association for the Study of Pain (EFIC) are from a multinational, crossover trial comparing Instanyl with oral transmucosal fentanyl citrate (OTFC) for the treatment of breakthrough pain in patients with cancer.

11 Sep 2009

Study investigating the effect of FTO obesity gene in relation to food habits

The risk of becoming obese is 2.5 times higher for those who have double copies of the best known risk gene for overweight and obesity. However, this is only true if the fat consumption is high. A low fat diet neutralizes the harmful effects of the gene.

11 Sep 2009

HALO Pap test for the breast to be featured in a healthcare talk show

The HALO Pap Test for the Breast -- which helps assess a woman’s risk of developing breast cancer -- will be featured this Friday Sept. 11 on the popular daytime healthcare talk show by co-host Lisa Masterson, MD, an ob/gyn in Santa Monica, Calif.

11 Sep 2009

Cancer News and Research

Latest Cancer News and Research

University of Surrey lecturer on Co-sleeping

Immigration and education policies to impact United states' leadership in science and discovery

Abell Foundation plays major role in BioMarker's $1.7M private placement funding

Genspera to commence G-202 Phase I trial following FDA approval

USPTO allows Isis an additional patent for single-stranded RNAi technology

RWJF selects Regions Hospital to take part in its effort to improve cardiac care delivered in hospitals

Delcath Systems to continue Phase III clinical trial

Roche scientists use their xCELLigence System to analyze nutlin-induced apoptosis

Abstracts on Merck Serono oncology treatments to be presented at ECCO and ESMO

Hospital of Saint Raphael implements Think First’s Instant Informatics revenue cycle tool

Solos obtains purchase order for surgical endoscopy instruments

New stem cell technology could destroy breast cancer cells

HHS Secretary to issue new report on the employer-sponsored insurance market

ThromboGenics shortlisted for two awards at the Scrip Awards 2009

Update on Prolindac clinical development plan provided by Access Pharmaceuticals

Cellular mechanosensory system may yield new insights for cancer therapy

Amylin and Biocon collaborate to develop a peptide therapeutic for treating diabetes

New data reveals the efficacy of Instanyl in management of breakthrough cancer pain

Study investigating the effect of FTO obesity gene in relation to food habits

HALO Pap test for the breast to be featured in a healthcare talk show

Cancer Research eBook

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Cancer News and Research

Latest Cancer News and Research

Cancer Research eBook

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Newsletters you may be interested in